A new CEO, a $5 billion share-repurchase program, and a handful of promising new drugs make Pfizer shares look cheap even after today's runup, according to Morningstar's Damien Conover.
Good day everyone and welcome to Pfizer s First Quarter 2010 Earnings Conference Call. Today s call is being recorded.
Good day everyone, and welcome to Pfizer s Third Quarter 2010 Earnings Conference Call. Today s call is being recorded.
Good morning. Thank you for joining us today to review Pfizer's Second Quarter 2010 Performance, 2010 financial guidance, and 2012 long-range target. I'm here with Jeff Kindler , Frank D'Amelio, Ian Read and other members of our leadership team.